

# Comprehensive Inventory of Research Grants 1997 – 2014

NO.	GRANT TITLE	RESEARCHER	UNIVERSITY OR INSTITUTION	YEAR	AMOUNT	GENERAL AREA OF RESEARCH
001	Presence and Amount of Glycation & Oxidation Markers in PSP	Massimo Tabaton, MD	University of Genoa, Department of Neurosciences Genoa, Italy	1997	\$ 10,000	(2) Non-Tau Based Pathologies: Mitochondrial, Radicals, Cell Death
002	Genetics and Environmental Studies of Bodig and Lytico in Villages of Southern Guam	John C. Steele, MD	Guam Memorial Hospital Tamuning, Guam	1997	\$ 10,000	(5) Toxins and Epidemiology (7) Clinical, Non-Treatment-Oriented Research
003	Ferritin is Associated with the Aberrant Tau Filaments Present in PSP	Jesus Avila, PhD	Centro De Biologica Molecular Madrid, Spain	1997	\$ 9,700	(1) Tau: Genetics, Biochemistry and Treatment Target (b. Biochemistry of tau and tangles)
005	Linkage Analysis in Familial PSP (To Perform Linkage Analysis in a Large Spanish Family with PSP)	Justo Garcia de Yebenes, MD, PhD	Universidad Autonoma de Madrid Madrid, Spain	1997	\$ 10,000	(3) Non-Tau Based Genetic Studies
006	Reaction Time and Acoustic Startle in Patients with PSP, Multi-System Atrophy, and Parkinson's Disease	Josep Valls-Sole, MD	Hospital Clinic Barcelona, Spain	1997	\$ 10,000	(7) Clinical, Non-Treatment-Oriented Research
007	The History of PSP	Adolfo Brusa, MD	Corso A. Saffi Genoa, Italy	1997	\$ 1,200	(5) Toxins and Epidemiology (7) Clinical, Non-Treatment-Oriented Research
008	Haplotype Relative Risk Analysis in PSP	Lawrence I. Golbe, MD, A. M. Lazzarini, PhD	UMDNJ Robert Wood Johnson Medical School New Brunswick, NJ	1997	\$ 20,000	(1) Tau: Genetics, Biochemistry and Treatment Target (a. The tau gene)
101	Establishment of a PSP Brain Bank	Dennis Dickson, MD	Mayo Clinic Jacksonville, FL	1998	\$ 20,000	(8) Brain Bank
102	Trial of Donepezil HCL in PSP Patients	Irene Litvan, MD	Henry M. Jackson Foundation Bethesda, MD	1998	\$ 29,200	(6) Clinical and Laboratory Treatment-Oriented Research
103	Potential Role of Mitochondrial Defects in PSP	M. Flint Beal, MD	Cornell University, Weill Medical College New York, NY	1998	\$ 20,000	(2) Non-Tau Based Pathologies: Mitochondrial, Radicals, Cell Death
104	Molecular Studies of the Tau Gene in PSP	William G. Johnson, MD Lawrence I. Golbe, MD	UMDNJ Robert Wood Johnson Medical School New Brunswick, NJ	1998	\$ 20,000	(1) Tau: Genetics, Biochemistry and Treatment Target (a. The tau gene)
105	Oxidative Mechanisms in PSP	David S. Albers, PhD	Massachusetts General Hospital, Neurology Dept. Boston, MA	1998	\$ 20,000	(2) Non-Tau Based Pathologies: Mitochondrial, Radicals, Cell Death
106	Tau Gene Mutations in PSP	Joseph J. Higgins, MD	Laboratory of Clinical Neurogenetics, Wadsworth Center Albany, NY	1998	\$ 20,000	(1) Tau: Genetics, Biochemistry and Treatment Target (a. The tau gene)
107	Mitochondria in PSP	Russell Swerdlow, MD	University of Virginia, School of Medicine Charlottesville, VA	1998	\$ 17,000	(2) Non-Tau Based Pathologies: Mitochondrial, Radicals, Cell Death (3) Non-Tau Based Genetic Studies
108	Neuroanatomical Basis for PSP Eyelid Motor Dysfunction	Mark S. LeDoux, MD, PhD	University of Tennessee Health Science Center Memphis, TN	1998	\$ 20,000	(4) Anatomic and Histopathological Surveys
109	Neuropathological Grading Scale for PSP	Mark W. Becher, MD	University of New Mexico, Health Sciences Center Albuquerque, NM	1998	\$ 10,000	4) Anatomic and Histopathological Surveys

# Comprehensive Inventory of Research Grants 1997 – 2014

NO.	GRANT TITLE	RESEARCHER	UNIVERSITY OR INSTITUTION	YEAR	AMOUNT	GENERAL AREA OF RESEARCH
201	Synaptic Protein Loss and Alterations in Growth Inhibitory Factors as a Biological Foundation of Behavioural Changes & Cognitive Decline in PSP	Elizabeth B. Mukaetova-Ladinska, MD	Newcastle University Newcastle upon Tyne, United Kingdom	1999	\$ 25,000	(4) Anatomic and Histopathological Surveys (7) Clinical, Non-Treatment- Oriented Research
202	Mechanisms of Neurofibrillary Tangle Formation in PSP	Nancy A. Muma, PhD	Loyola University Chicago Maywood, IL	1999	\$ 20,000	(1) Tau: Genetics, Biochemistry and Treatment Target (b. Biochemistry of tau and tangles)
203	Is Brain Oxidative Stress & Damage Characteristic of PSP?	Stephen J. Kish, PhD	Centre for Addiction & Mental Health Toronto, ON	1999	\$ 25,000	(2) Non-Tau Based Pathologies: Mitochondrial, Radicals, Cell Death
204	Role of the Thalamus in PSP and Parkinson's Disease	Jasmine Henderson, PhD	Prince of Wales Medical Research Institute Randwick, Australia	1999	\$ 25,000	(4) Anatomic and Histopathological Surveys
206	Identification of the PSP Gene	Parvoneh Navas, PhD	University of Washington Seattle, WA	1999	\$ 25,000	(1) Tau: Genetics, Biochemistry and Treatment Target (a. The tau gene)
207	Problems of Cell Death in PSP	Kurt A. Jellinger, MD	University of Vienna, School of Medicine Vienna, Austria	1999	\$ 18,000	(2) Non-Tau Based Pathologies: Mitochondrial, Radicals, Cell Death
208	Activity and Expression of Antioxidant Enzymes in the PSP Brain	Sarah Jane Augood, PhD	Massachusetts General Hospital Boston, MA	1999	\$ 20,000	(2) Non-Tau Based Pathologies: Mitochondrial, Radicals, Cell Death
209	Are Impairments of Energy Metabolism Contributory in PSP?	M. Flint Beal, MD	Cornell University, Weill Medical College New York, NY	1999	\$ 19,929	(2) Non-Tau Based Pathologies: Mitochondrial, Radicals, Cell Death
210	Ultrastructural and Biochemical Heterogeneity of Paired Helical Filaments in PSP	Hanna Ksiezak-Reding, PhD	Mount Sinai School of Medicine New York, NY	1999	\$ 18,000	(1) Tau: Genetics, Biochemistry and Treatment Target (b. Biochemistry of tau and tangles)
211	Mutational Analysis of the Tau Gene in PSP	Joseph J. Higgins, MD	New York State Dept. of Health, New York, NY	1999	\$ 20,000	(1) Tau: Genetics, Biochemistry and Treatment Target (a. The tau gene)
300	Environmental Factors and Detoxification Mechanisms in PSP	Rosemary S. Waring, MA, PhD	University of Birmingham Birmingham, United Kingdom	2000	\$ 20,000	(6) Clinical and Laboratory Treatment-Oriented Research
301	Regulation of Human Tau Gene Expression and its Role in PSP	Jane Wu, PhD	Washington University, School of Medicine St. Louis, MO	2000	\$ 20,000	(1) Tau: Genetics, Biochemistry and Treatment Target (a. The tau gene)
303	Are Matrix Metalloproteinases Involved in the Pathogenesis of PSP?	David S. Albers, PhD	Cornell University, Weill Medical College New York, NY	2000	\$ 20,000	(2) Non-Tau Based Pathologies: Mitochondrial, Radicals, Cell Death
304	Effect of Lipoperxidation on cdk5 Activity and Tau Protein Aggregation: A Model of PSP Pathogenesis	Massimo Tabaton, MD	University of Genoa, Department of Neurosciences Genoa, Italy	2000	\$ 20,000	(1) Tau: Genetics, Biochemistry and Treatment Target (b Biochemistry of tau and tangles) (2) Non-Tau Based Pathologies: Mitochondrial, Radicals, Cell Death
400	Dopa-resistant Parkinsonism in Guadeloupe: Evaluation of Isoquinolines Derivates and Acetogenines Toxicity in Rats	Dominique Caparros-Lefebvre, MD	University Hospital Guadeloupe, France	2001	\$ 50,000	(5) Toxins and Epidemiology

# Comprehensive Inventory of Research Grants 1997 – 2014

NO.	GRANT TITLE	RESEARCHER	UNIVERSITY OR INSTITUTION	YEAR	AMOUNT	GENERAL AREA OF RESEARCH
401	mRNA Profiling in the Postmortem PSP Brain: Identifying Abnormal Signaling Pathways	Sarah Jane Augood, PhD	Massachusetts General Hospital Boston, MA	2001	\$ 47,500	(4) Anatomic and Histopathological Surveys
402	Comparison of Region Specific mRNA Expression Profiles of PSP Brains with those of Alzheimer, FTDP-17, Pick Disease & Non Affected Brains, Using DNA Microarray Technology	Vincenzo Bonifati, MD	Erasmus University Rotterdam, The Netherlands	2001	\$ 45,000	(4) Anatomic and Histopathological Surveys
403	Mechanisms Regulating Neurofibrillary Tangle Formation in PSP	Nancy A. Muma, PhD	University of Washington Seattle, WA	2001	\$ 42,406	(1) Tau: Genetics, Biochemistry and Treatment Target (b. Biochemistry of tau and tangles)
404	Tau Auto-Antibody Production in PSP	James W. Tetrad, MD	The Parkinson's Institute, Research and Treatment Center Sunnyvale, CA	2001	\$ 38,976	(1) Tau: Genetics, Biochemistry and Treatment Target (b. Biochemistry of tau and tangles)
405	Regulation of Human Tau Gene Expression and its Role in PSP	Jane Wu, PhD	Washington University, School of Medicine St. Louis, MO	2000	\$ 25,794	(1) Tau: Genetics, Biochemistry and Treatment Target (a. The tau gene)
406	Characterization of the Molecular Mechanisms Leading to PSP	Justo Garcia de Yebenes, MD, PhD	Fundacion Jimenez Diaz Madrid, Spain	2001	\$ 45,000	(1) Tau: Genetics, Biochemistry and Treatment Target (b. Biochemistry of tau and tangles)
407	Interaction of Parkin Protein with Abnormal Tau	Paul S. Fishman, MD	University of Maryland, School of Medicine Baltimore, MD	2001	\$ 40,000	(1) Tau: Genetics, Biochemistry and Treatment Target (b. Biochemistry of tau and tangles) (3) Non-Tau Based Genetic Studies
408	Finding the Cause and Effect of a Bioenergetic Defect in PSP	David S. Albers, PhD	Cornell University, Weill Medical College New York, NY	2001	\$ 49,775	(2) Non-Tau Based Pathologies: Mitochondrial, Radicals, Cell Death
409	Eloise H. Troxel Memorial Brain Bank	Dennis Dickson, MD	Mayo Clinic Jacksonville, FL	2001	\$ 60,000	(8) Brain Bank
410	Development of a Measure of Health-Related Quality of Life PSP	Anette Schrag, MD, PhD	University College London London, United Kingdom	2002	\$ 46,711	(7) Clinical, Non-Treatment-Oriented Research
411	Glial Tau Aggregates in PSP and Human Cultured Cells	Hanna Ksiezak-Reding, PhD	Mount Sinai School of Medicine, Department of Psychiatry New York, NY	2002	\$ 50,000	(1) Tau: Genetics, Biochemistry and Treatment Target (b. Biochemistry of tau and tangles)
412	Cortial and Striatial Cholinergic Receptor Subtypes in PSP, Alzheimer's Disease and Dementia with Lewy Bodies	David J. Burn, MD	Newcastle General Hospital, Regional Neuroscience Centre Newcastle upon Tyne, United Kingdom	2002	\$ 46,314	(4) Anatomic and Histopathological Surveys
413	Analysis of the 17q21 Region in PSP, Tau Gene Analysis in Parkinson's Disease Dementia and in Other Atypical Parkinsonisms	Eduardo Tolosa, MD, PhD	Hospital Clinic, Neurology Service Barcelona, Spain	2002	\$ 36,000	(1) Tau: Genetics, Biochemistry and Treatment Target (a. The tau gene)

# Comprehensive Inventory of Research Grants 1997 – 2014

NO.	GRANT TITLE	RESEARCHER	UNIVERSITY OR INSTITUTION	YEAR	AMOUNT	GENERAL AREA OF RESEARCH
414	Screening of Tau Mutation in a Unique PSP Family	Rong Chen, MD, PhD	The Parkinson's Institute, Research & Treatment Center Sunnyvale, CA	2002	\$ 14,250	(1) Tau: Genetics, Biochemistry and Treatment Target (a. The tau gene)
415	Characterization of Tau Auto-Antibodies in PSP	James W. Tetrud, MD	The Parkinson's Institute, Research & Treatment Center Sunnyvale, CA	2002	\$ 30,010	(1) Tau: Genetics, Biochemistry and Treatment Target (b. Biochemistry of tau and tangles)
416	Cross-Linking of Tau in PSP Neurofibrillary	Nancy A. Muma, PhD	Loyola University Chicago Maywood, IL	2002	\$ 49,998	(1) Tau: Genetics, Biochemistry and Treatment Target (b. Biochemistry of tau and tangles)
417	Prehistory of PSP: Bibliographic Search and Copying	Adolfo Brusa, MD	Ospedalia Galliera Genoa, Italy	2002	\$ 3,000	(7) Clinical, Non-Treatment-Oriented Research
418	The Relationship of Guamanian Pigmentary Retinopathy to ALS/PDC of Guam	John C. Steele, MD	Guam Memorial Hospital Tamuning, Guam	2002	\$ 48,300	(7) Clinical, Non-Treatment-Oriented Research
419	Efficacy of Environmental on a Mouse Models of Tauopathy	Jada Lewis, PhD	Mayo Clinic Jacksonville, FL	2002	\$ 49,987	(1) Tau: Genetics, Biochemistry and Treatment Target (b. Biochemistry of tau and tangles)
420	A Novel Approach for Neuroprotection in PSP	Irene Litvan, MD	Henry M. Jackson Foundation Bethesda, MD	2002	\$ 45,460	(6) Clinical and Laboratory Treatment-Oriented Research
421	Diagnostic Protein Biomarker Discovery in PSP	Lap Ho, PhD	Washington University, School of Medicine St. Louis, MO	2003	\$ 50,000	(4) Anatomic and Histopathological Surveys (7) Clinical, Non-Treatment-Oriented Research
422	mRNA Profiling in the Postmortem PSP Brain: Target Identification	Sarah Jane Augood, PhD	Massachusetts General Hospital Boston, MA	2003	\$ 50,000	(4) Anatomic and Histopathological Surveys
423	Identification of Cis-Elements that Regulate Exon 10 Splicing in the Tau Gene	Jianhua Zhou, PhD	University of Massachusetts Medical School Worcester, MA	2003	\$ 46,540	(1) Tau: Genetics, Biochemistry and Treatment Target (a. The tau gene, b. Biochemistry of tau and tangles)
424	Hyperphosphorylation, Tau Filaments and Neurodegeneration in a Transgenic Mouse Model of a Human Tauopathy	Maria Grazia Spillantini, PhD	University of Cambridge Cambridge, United Kingdom	2003	\$ 50,000	(1) Tau: Genetics, Biochemistry and Treatment Target (b. Biochemistry of tau and tangles)
425	Genetic Analysis of 17q21 Region Sporadic Tauopathies	Alison M. Goate, DPhil	Washington University, School of Medicine St. Louis, MO	2003	\$ 25,000	(1) Tau: Genetics, Biochemistry and Treatment Target (a. The tau gene)
426	Development and Characterization of a Novel Experimental Model of PSP	Etienne C. Hirsch, PhD	Hospital de la Salpêtrière Paris, France	2003	\$ 48,700	(5) Toxins and Epidemiology
427	Aging Effects and Gene Therapy in a Novel Nigrostriatal Degeneration Model	Ronald L. Klein, MD	Louisiana State University, Health Sciences Center Shreveport, LA	2003	\$ 50,000	(6) Clinical and Laboratory Treatment-Oriented Research
428	Refining the Genetic and Functional Role of the Tau H1 Haplotype in Neurodegeneration	Matt Farrer, PhD	Mayo Clinic Jacksonville, FL	2003	\$ 50,000	(1) Tau: Genetics, Biochemistry and Treatment Target (a. The tau gene)
429	Formation Filamentous Tau Inclusions in Human Cells with Inducible Expression of Tau Proteins	Shu-Hui Yen, PhD	Mayo Clinic Jacksonville, FL	2003	\$ 50,000	(1) Tau: Genetics, Biochemistry and Treatment Target (b. Biochemistry of tau and tangles)

# Comprehensive Inventory of Research Grants 1997 – 2014

NO.	GRANT TITLE	RESEARCHER	UNIVERSITY OR INSTITUTION	YEAR	AMOUNT	GENERAL AREA OF RESEARCH
430	Cystamine, a Transglutaminase Inhibitor, for the Treatment of Tauopathies, Especially in PSP	Nancy A. Muma, PhD	University of Washington Seattle, WA	2003	\$ 44,000	(1) Tau: Genetics, Biochemistry and Treatment Target (c. Tau as a treatment target) (6) Clinical and Laboratory Treatment-Oriented Research
431	Discovery of Tau Phosphorylation Inhibitors for the Treatment of PSP	Kenneth S. Kosik, MD	Brigham and Women's Hospital Boston, MA	2003	\$ 44,000	(1) Tau: Genetics, Biochemistry and Treatment Target (c. Tau as a treatment target) (6) Clinical and Laboratory Treatment-Oriented Research
432	Correlation of Clinical Severity, Brain Inflammatory Changes & Apparent Water Diffusion Coefficients in PSP & Idiopathic Parkinson's Disease	David J. Brooks, MD	Imperial College School of Medicine London, United Kingdom	2003	\$ 44,000	(7) Clinical, Non-Treatment-Oriented Research
433	Parkin Mutations in a Mouse Model of PSP	Parvoneh Navas, PhD	University of Washington Seattle, WA	2003	\$ 44,000	(1) Tau: Genetics, Biochemistry and Treatment Target (b. Biochemistry of tau and tangles) (3) Non-Tau Based Genetic Studies
434	Eloise H. Troxel Memorial Brain Bank	Dennis Dickson, MD	Mayo Clinic Jacksonville, FL	2003	\$ 25,000	(8) Brain Bank
435	Assesment of Tau Protein Isoform Profile in Cerebrospinal Fluid of Tauopathy Patients as a Potential Diagnostic Biomarker	Rohan de Silva, DPhil	University College London London, United Kingdom	2004	\$ 36,898	(1) Tau: Genetics, Biochemistry and Treatment Target (b. Biochemistry of tau and tangles) (7) Clinical, Non-Treatment Oriented Research
436	Proteomic Analysis of a Transgenic Mouse Model of Tauopathy	Shu-Hui Yen, PhD	Mayo Clinic Jacksonville, FL	2004	\$ 46,000	(1) Tau: Genetics, Biochemistry and Treatment Target (d. Tau modulation of other cell processes)
437	Heat Shock Proteins as Inhibitors of Tau Aggregation in Oligodendrocytes	Christine Richter-Landsberg, MD	University of Oldenburg Oldenburg, Germany	2004	\$ 46,000	(1) Tau: Genetics, Biochemistry and Treatment Target (c. Tau as a treatment target)
438	Proteomis Analysis of Post Mortem PSP Brain	Benoit Giasson, PhD	University of Pennsylvania Philadelphia, PA	2004	\$ 46,000	(4) Anatomic and Histopathological Surveys
439	Identification of Compounds that Modulate Exon 10 Splicing in the Tau Gene	Jianhua Zhou, PhD	University of Massachusetts Medical School Worcester, MA	2004	\$ 40,000	(1) Tau: Genetics, Biochemistry and Treatment Target (c. Tau as a treatment target) (6) Clinical and Laboratory Treatment-Oriented Research
440	PSP and a Failing Ubiquitin-Proteasome System	F. W. van Leeuwen, PhD	Netherlands Institute for Brain Research Amsterdam, The Netherlands	2004	\$ 45,000	(4) Anatomic and Histopathological Surveys
441	A Zebrafish Model of Tauopathy	Edward Burton, MD	University of Pittsburgh Pittsburgh, PA	2005	\$ 49,941	(1) Tau: Genetics, Biochemistry and Treatment Target (c. Tau as a treatment target)
442	Proteomics Analysis of a Novel Murine Model of Astrocytic Tau Pathology in PSP	Mark S. Forman, MD, PhD	University of Pennsylvania Philadelphia, PA	2005	\$ 50,000	(1) Tau: Genetics, Biochemistry and Treatment Target (d. Tau modulation of other cell processes)
444	Effect of Coenzyme Q10 in PSP: A Randomized, Multicenter, Placebo-Controlled, Double Blind Study	Diana Apetauerova, MD	Lahey Clinic Burlington, MA	2005	\$ 50,000	(6) Clinical and Laboratory Treatment-Oriented Research

# Comprehensive Inventory of Research Grants 1997 – 2014

NO.	GRANT TITLE	RESEARCHER	UNIVERSITY OR INSTITUTION	YEAR	AMOUNT	GENERAL AREA OF RESEARCH
445	Do PSP-Associated TAU Polymorphisms Alter the Expression of the TAU Microtubule Binding Domain?	Hana N. Dawson, PhD	Duke University Medical Center Durham, NC	2005	\$ 50,000	(1) Tau: Genetics, Biochemistry and Treatment Target (a. The tau gene)
446	Inhibiting Transglutaminase Splice Variants for Treatment of PSP	Nancy A. Muma, PhD	Loyola University Chicago Maywood, IL	2005	\$ 50,000	(1) Tau: Genetics, Biochemistry and Treatment Target (c. Tau as a treatment target) (6) Clinical and Laboratory Treatment-Oriented Research
447	Eloise H. Troxel Memorial Brain Bank	Dennis Dickson, MD	Mayo Clinic Jacksonville, FL	2005	\$ 25,000	(8) Brain Bank
448	AKT-Dependent Signaling in PSP and Transgenic Mouse Model of Tauopathy	Hanna Ksiezak-Reding, PhD	Mount Sinai School of Medicine New York, NY	2005	\$ 50,000	(1) Tau: Genetics, Biochemistry and Treatment Target (b. Biochemistry of tau and tangles, d. Tau modulation of other cell processes)
449	Studies of PSA Neuroprotective Role Using Transgenic Mouse Models	Stanislav L. Karsten, PhD	University of California, Los Angeles Los Angeles, CA	2006	\$ 50,000	(1) Tau: Genetics, Biochemistry and Treatment Target (c. Tau as a treatment target) (6) Clinical and Laboratory Treatment-Oriented Research
450	Hypothesis-Driven Gene Profiling in an Animal Model of PSP	Ronald L. Klein, MD	Louisiana State University Health Sciences Center Shreveport, LA	2006	\$ 50,000	(1) Tau: Genetics, Biochemistry and Treatment Target (b. Biochemistry of tau and tangles, d. Tau modulation of other cell processes)
451	Interaction of Neuronal and Glial Tau in a Drosophila Model of Tauopathy	Mel B. Feany, MD, PhD	Brigham and Women's Hospital Boston, MA	2006	\$ 50,000	(1) Tau: Genetics, Biochemistry and Treatment Target (b. Biochemistry of tau and tangles, d. Tau modulation of other cell processes)
452	Finemapping of Risk Loci for PSP Identified in a Genome-Wide Scan	Michael Hutton, PhD	Mayo Clinic Jacksonville, FL	2006	\$ 50,000	(3) Non-Tau Based Genetic Studies
453	Parkin and Tau Mutational Effects on Tangle Formation in PSP	Parvoneh Navas, PhD	University of Washington Seattle, WA	2006	\$ 50,000	(1) Tau: Genetics, Biochemistry and Treatment Target (b. Biochemistry of tau and tangles)
454	Tau Aggregation in Oligodendrocytes and the Role of Thrombin Signaling	Christine Richter-Landsberg, MD	University of Oldenburg Oldenburg, Germany	2007	\$ 104,000	(1) Tau: Genetics, Biochemistry and Treatment Target
455	Strength Training Patients with PSP for Dysphagia	Christine Sapienza, PhD Huber Fernandez, MD	University of Florida Gainesville, FL	2007	\$ 94,327	(6) Clinical and Laboratory Treatment-Oriented Research
456	Inhibition of Tau Pathology in Transgenic Mouse Models with an Optimized Orally Active Tau Kinase Inhibitor	Hanno M. Roder, PhD Michael L. Hutton, PhD	Mayo Clinic Jacksonville, FL	2007	\$ 250,000	(6) Clinical and Laboratory Treatment-Oriented Research
457	Genome-Wide Association Study in PSP	Ulrich Müller, MD, PhD Günter Höglinger, MD	University Hospital Giessen, Germany	2007	\$ 200,000	(3) Non-Tau Based Genetic Studies
458	Unraveling Multi-Protein Chaperone Complexes in PSP and Other Tauopathies	Chad Dickey, PhD	University of Oxford Oxford, United Kingdom	2007	\$ 150,000	(2) Non-Tau Based Pathologies: Mitochondrial, Radicals, Cell Death
459	Haplotype Regulation of Alternative Splicing at the MAPT Locus	Richard Wade-Martins, MA, DPhil	University of Oxford Oxford, United Kingdom	2007	\$ 150,000	(1) Tau: Genetics, Biochemistry and Treatment Target (b. Biochemistry of tau and tangles, d. Tau modulation of other cell processes)
460	Longitudinal Prospective PSP Study	Irene Litvan, MD	University of Louisville Louisville, KY	2007	\$ 100,000	(5) Toxins and Epidemiology

# Comprehensive Inventory of Research Grants 1997 – 2014

NO.	GRANT TITLE	RESEARCHER	UNIVERSITY OR INSTITUTION	YEAR	AMOUNT	GENERAL AREA OF RESEARCH
461	Genome-Wide Association Study in PSP	Gerard Schellenberg, PhD Chang-En Yu, PhD	Geriatric Research Education and Clinical Center Seattle, WA	2007	\$ 96,700	(3) Non-Tau Based Genetic Studies
462	Genome-Wide Association Study in PSP	Bernie Devlin, PhD	University of Pittsburgh Pittsburgh, PA	2007	\$ 20,000	(3) Non-Tau Based Genetic Studies
463	Genome-Wide Association Study in PSP	Hank Hakonarson, PhD	Children's Hospital of Philadelphia, Center for Applied Genomics Philadelphia, PA	2007	\$ 580,000	(3) Non-Tau Based Genetic Studies
464	Genome-Wide Association Study in PSP	Ulrich Müller, MD, PhD Günter Höglinger, MD	University Hospital Giessen, Germany	2007	\$ 70,700	(3) Non-Tau Based Genetic Studies
465	Genome-Wide Association Study in PSP	Rohan de Silva, DPhil John Hardy, PhD Andrew Lees, MD, FRCP	University College London London, United Kingdom	2007	\$ 20,000	(3) Non-Tau Based Genetic Studies
466	Genome-Wide Association Study in PSP	Dennis Dickson, MD Matthew Farrer, MD Rosa Rademakers, PhD	Mayo Clinic Jacksonville, FL	2007	\$ 29,700	(3) Non-Tau Based Genetic Studies
467	Mapping Progressive Neurodegeneration in PSP using Transcranial Magnetic Stimulation and CSF-Tau	David Williams, PhD, FRACP	Monash University Melbourne, Australia	2008	\$ 50,000	(7) Clinical, Non-Treatment Oriented Research
468	Phenotypic Characterization of Tauopathy Zebrafish	Edward Burton, MD	University of Pittsburgh Pittsburgh, PA	2008	\$ 50,000	(1) Tau: Genetics, Biochemistry and Treatment Target (b. Biochemistry of tau and tangles, d. Tau modulation of other cell processes)
469	Toward a Molecular Understanding of Tau Misfolding	Martin Margittai, PhD	University of Denver Denver, CO	2008	\$ 100,000	(1) Tau: Genetics, Biochemistry and Treatment Target (b. Biochemistry of tau and tangles, d. Tau modulation of other cell processes)
470	Noninvasive Cortical Stimulation for Motor and Non-Motor Features of PSP and CBD	Allen Wu, MD	University of California, San Francisco San Francisco, CA	2008	\$ 100,000	(6) Clinical and Laboratory Treatment-Oriented Research
471	Unilateral Pedunculopontine Deep Brain Stimulation in PSP	Elena Moro, MD	University of Toronto Toronto, ON	2008	\$ 100,000	(6) Clinical and Laboratory Treatment-Oriented Research
472	Eloise H. Troxel Memorial Brain Bank	Dennis Dickson, MD	Mayo Clinic Jacksonville, FL	2008	\$ 50,000	(8) Brain Bank
473	The Role of Microglial-mediated Neuroinflammation in Fronto-Temporal Dementia Tau Pathology	Kiran Bhaskar, PhD	Cleveland Clinic Florida Tampa, FL	2009	\$ 150,000	(2) Non-Tau Based Pathologies: Mitochondrial, Radicals, Cell Death
474	Targeting Hsp70 as a Therapeutic Strategy for CBD and Other Tauopathies	Chad Dickey, PhD	University of South Florida Tampa, FL	2009	\$ 250,000	(6) Clinical and Laboratory Treatment-Oriented Research
475	The Effects of CBD-Associated Tau Gene H1 Haplotype on Tau Tauopathies	Hana N. Dawson, PhD	Duke University Medical Center Durham, NC	2009	\$ 250,000	(1) Tau: Genetics, Biochemistry and Treatment Target
476	Polyphenols from Grape Seeds as a Potential Therapeutic Agent in Tauopathies	Giulio Maria Pasinetti, MD, PhD	Mount Sinai School of Medicine New York, NY	2009	\$ 250,000	(6) Clinical and Laboratory Treatment-Oriented Research
477	A Pilot Clinical Trial of HAP (AL-108) for CBD and Frontotemporal Labor Degeneration with Predicted CBD Pathology	Adam Boxer, MD, PhD	University of California, San Francisco San Francisco, CA	2009	\$ 250,000	(6) Clinical and Laboratory Treatment-Oriented Research

# Comprehensive Inventory of Research Grants 1997 – 2014

NO.	GRANT TITLE	RESEARCHER	UNIVERSITY OR INSTITUTION	YEAR	AMOUNT	GENERAL AREA OF RESEARCH
478	Genome-Wide Identification of Transregulators of Tau Gene Expression & Splicing	Rohan de Silva, DPhil John Hardy, PhD	University College London London, United Kingdom	2009	\$ 209,119	(1) Tau: Genetics, Biochemistry and Treatment Target
479	HSP-Peptide Complex Mediated Immunization in a Mouse Model of Tauopathy	Michael DeTure, PhD	Mayo Clinic Jacksonville, FL	2009	\$ 210,000	(8) Molecular and Cellular Abnormalities
480	In Vivo Identification of Pharmacological Treatments for Tauopathy	Mel B. Feany, MD, PhD	Brigham and Women's Hospital Boston, MA	2009	\$ 217,500	(6) Clinical and Laboratory Treatment-Oriented Research
481	Tau-Mediated Effects Upon Microtubule Structure and Kinesin Translocation	Stuart Feinstein, PhD	University of California, San Francisco San Francisco, CA	2009	\$ 226,493	(8) Molecular and Cellular Abnormalities
482	Development of Activators of Puromycin Sensitive Aminopeptidase to Treat CBD	Stanislav L. Karsten, PhD	Los Angeles Biomedical Research Institute Los Angeles, CA	2009	\$ 217,483	(6) Clinical and Laboratory Treatment-Oriented Research
483	Comparative Proteomics of CBD & PSP Brain to Identify Biomarkers	Jayanarayan Kulathingal, PhD	Mayo Clinic Jacksonville, FL	2009	\$ 156,205	(8) Molecular and Cellular Abnormalities
484	Structural Polymorphism of Tau Filaments in CBD	Martin Margittai, PhD	University of Denver Denver, CO	2009	\$ 52,200	(8) Molecular and Cellular Abnormalities
485	MicroRNA Regulation of MAPT in CBD and Related Tauopathies	Rosa Rademakers, PhD	Mayo Clinic Jacksonville, FL	2009	\$ 217,500	(1) Tau: Genetics, Biochemistry and Treatment Target
486	Inhibition of Tau Pathology in Transgenic Mouse Models with an Optimized Orally Active Tau Kinase Inhibitor	Hanno M. Roder, PhD Michael L. Hutton, PhD	TauTaTis, Inc. Jacksonville, FL	2009	\$ 126,000	(6) Clinical and Laboratory Treatment-Oriented Research
487	Modeling Haplotype-Specific Gene Function at the MAPT Locus in 4R Tauopathy	Richard Wade-Martins, MA, DPhil	University of Oxford Oxford, United Kingdom	2009	\$ 217,500	(1) Tau: Genetics, Biochemistry and Treatment Target
488	Autophagic Modulation and Clearance of Tau Aggregates	W. Haung (Ho) Yu, PhD	Columbia University Medical Center New York, NY	2010	\$ 75,000	(1) Tau: Genetics, Biochemistry and Treatment Target
489	Tau and its Pathology in Neurons Derived from Induced Pluripotent Stem Cells of FTDP-17T Patients with PSP-Like Tau Pathology	Maria Grazia Spillantini, PhD	University of Cambridge Cambridge, United Kingdom	2010	\$ 75,000	(1) Tau: Genetics, Biochemistry and Treatment Target
490	Eloise H. Troxel Memorial Brain Bank	Dennis Dickson, MD	Mayo Clinic Jacksonville, FL	2010	\$ 66,000	(8) Brain Bank
491	PSP/CBD Genome-Wide Association Analysis Follow-up and Replication	Gerard Schellenberg, PhD Chang-En Yu, PhD	University of Pennsylvania Philadelphia, PA	2010	\$ 137,257	(1) Tau: Genetics, Biochemistry and Treatment Target
492	Pathogenetic Mechanisms of Progressive Supranuclear Palsy and Corticobasal Degeneration	Gerard Schellenberg, PhD Chang-En Yu, PhD	University of Pennsylvania Philadelphia, PA	2010	\$ 250,000	(1) Tau: Genetics, Biochemistry and Treatment Target
493	A Pilot Clinical Trial of HAP (AL-108) for CBD and FTL Degeneration with Predicted CBD Pathology (see #501)	Adam Boxer, MD, PhD	University of California San Francisco, CA	2010	(see #501)	(6) Clinical and Laboratory Treatment-Oriented Research
494	Manipulating the Substrate Specificity Program in the Chaperone System to Remove Tau in PSP and CBD	Chad Dickey, PhD	University of South Florida Tampa, FL	2011	\$ 75,000	(1) Tau: Genetics, Biochemistry and Treatment Target
495	CHIP-Mediated Regulation of Hsp90 High Affinity Complex	Leonard Petrucelli, PhD	Mayo Clinic Jacksonville, FL	2011	\$ 50,000	(1) Tau: Genetics, Biochemistry and Treatment Target

# Comprehensive Inventory of Research Grants 1997 – 2014

NO.	GRANT TITLE	RESEARCHER	UNIVERSITY OR INSTITUTION	YEAR	AMOUNT	GENERAL AREA OF RESEARCH
496	Epigenetic Modifications in PSP CBD and Frontotemporal Labor Degeneration with Predicted CBD Pathology	Ulrich Müller, MD, PhD Günter Höglinger, MD	University Hospital Giessen & Marburg Giessen, Germany	2011	\$ 213,281	(3) Non-Tau Based Genetic Studies
497	Evaluating Reduced Tau Levels as a Therapy fo PSP and CBD	Timothy M. Miller, MD, PhD	Washington University School of Medicine St. Louis, MO	2011	\$ 75,000	(1) Tau: Genetics, Biochemistry and Treatment Target
498	Models to Determine the Toxicity of Tau Aggregates	T. Chris Gamblin, PhD	University of Kansas Lawrence, KS	2011	\$ \$75,000	(4) Anatomic and Histopathological Surveys
499	Eloise H. Troxel Memorial Brain Bank	Dennis Dickson, MD	Mayo Clinic Jacksonville, FL	2011	\$ 66,000	(8) Brain Bank
500	PSP Whole Exome Study - Phase One	Gerard Schellenberg, PhD	University of Pennsylvania Philadelphia, PA	2012	\$ 250,000	(1) Tau: Genetics, Biochemistry and Treatment Target
501	An Exploratory, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to the AL-108-231 of Davunetide	Adam Boxer, MD, PhD	University of California San Francisco, CA	2012	\$ 125,000	(6) Clinical and Laboratory Treatment-Oriented Research
502	Mechanisms of Tau and ER Stress for Novel PSP and CBD Therapeutics	Jose F. Abisambra, PhD	University of South Florida Tampa, FL	2012	\$ 75,000	(6) Clinical and Laboratory Treatment-Oriented Research
503	Gene Expression and Neuropathology Endophenotypes for Gene Discovery in PSP	Nilufer Ertekin-Taner, MD, PhD	Mayo Clinic Jacksonville, FL	2012	\$ 75,000	(2) Non-Tau Based Pathologies, Mitochondrial, Radicals, Cell Death
504	Identifying Functional Genetic Risk Factors for PSP by RNA-seq	Nilufer Ertekin-Taner, MD, PhD	Mayo Clinic Jacksonville, FL	2012	\$ 75,000	(3) Non-Tau Based Genetic Studies
505	Tracking Progressive Neurodegeneration in PSP Using Diffusion Tensor MRI	Massimo Filippi, MD	Vita-Salute San Raffaele University Milan, Italy	2012	\$ 62,000	(4) Anatomic and Histopathological Surveys
506	Eloise H. Troxel Memorial Brain Bank	Dennis Dickson, MD	Mayo Clinic Jacksonville, FL	2012	\$ 66,000	(8) Brain Bank
507	Splice Variant Markers for PSP Novel PSP and CBD Therapeutics	Judith Potashkin, PhD	Rosalind Franklin University of Medicine and Science Chicago, IL	2012	\$ 75,000	(1) Tau: Genetics, Biochemistry and Treatment Target
508	PSP Whole Exome Study Phase Two	Gerard Schellenberg, PhD	University of Pennsylvania Philadelphia, PA	2012	\$ 500,000	(1) Tau: Genetics, Biochemistry and Treatment Target
509	Tau Dimerization: A Mechanism of Tau Function and Dysfunction?	Stuart Feinstein, PhD	University of California Santa Barbara, CA	2013	\$ 75,000	(1) Tau: Genetics, Biochemistry and Treatment Target
510	Assessment of Guam ALS/PDC in 2013-14	Michael Geschwind, PhD John Steele, MD	University of California & Tau Consortium	2013	\$ 100,000	(5) Toxins and Epidemiology
511	Transgenic Rats Expressing Wild-Type and Mutant Human Tau	Stanley Prusiner, MD	University of California San Francisco, CA	2013	\$ 100,000	(1) Tau: Genetics, Biochemistry and Treatment Target
512	Mechanisms and Therapy for Tauopathy Based on RNA Binding Proteins	Benjamin Wolozin, MD, PhD	Boston University Boston, MA	2013	\$ 75,000	(6) Clinical and Laboratory Treatment-Oriented Research
513	Urso Student Fellowship	Emily Beisser	Rutgers Robert Wood Johnson Medical School New Brunswick, NJ	2013	\$ 3,000	(6) Clinical and Laboratory Treatment-Oriented Research
514	Eloise H. Troxel Memorial Brain Bank	Dennis Dickson, MD	Mayo Clinic Jacksonville, FL	2013	\$ 66,000	(8) Brain Bank

# Comprehensive Inventory of Research Grants 1997 – 2014

NO.	GRANT TITLE	RESEARCHER	UNIVERSITY OR INSTITUTION	YEAR	AMOUNT	GENERAL AREA OF RESEARCH
515	Follow-Up Genotyping and Functional Analysis of PSP H1 Haplotype Variants	Pau Pastor, MD, PhD	University of Navarra School of Medicine Pamplona, Spain	2013	\$ 75,000	(1) Tau: Genetics, Biochemistry and Treatment Target
516	Altering Tau Splicing for PSP and Other 4R Tauopathies	Michael Wolfe, PhD	Brigham and Women's Hospital Boston, MA	2014	\$ 75,000	(8) Molecular and Cellular Abnormalities
517	Development and Validation of the Unified CBD Rating Scale	Lawrence Golbe, MD Irene Litvan, MD	Rutgers Robert Wood Johnson Medical School New Brunswick, NJ University of California, San Diego San Diego, CA	2014	\$ \$75,000	(6) Clinical and Laboratory Treatment-Oriented Research
518	Epigenetic Modifications in PSP	Ulrich Müller, MD, PhD Günter Höglinger, MD	University Hospital Giessen & Marburg Giessen, Germany	2014	\$ 89,085	(1) Tau: Genetics, Biochemistry and Treatment Target
519	Disease-Modifying Tau Immune Therapy for PSP and CBD	John Trojanowski, PhD Virginia Lee, PhD	University of Pennsylvania Philadelphia, PA	2014	\$ 600,000	(1) Tau: Genetics, Biochemistry and Treatment Target
520	Impact of Arginase 1 Over-Expression and SAT1 Deficiency during Tauopathies	Daniel Lee, PhD	University of South Florida Tampa, FL	2014	\$ 100,000	(8) Molecular and Cellular Abnormalities
521	Whole Exome Sequencing Project	Gerard Schellenberg, PhD	University of Pennsylvania Philadelphia, PA	2014	\$ 100,000	(1) Tau: Genetics, Biochemistry and Treatment Target
522	The Role of O-Linked Protein Glycosylation in the Spread of Tau Pathology	Christoph Wiessner, PhD	Asceneuron SA Lausanne, Switzerland	2014	\$ 99,652	(1) Tau: Genetics, Biochemistry and Treatment Target
523	MOBP, STX6 and EIF2AK3 Expression and Distribution in PSP Brains	Rohan de Silva, DPhil	University College London London, United Kingdom	2014	\$ 75,049	(3) Non-Tau Based Genetic Studies
524	Synaptic Tau-Proteasome Dysfunction and a Potential Therapeutic Strategy	Natura Myeku, PhD	Columbia University New York, NY	2014	\$ 100,000	(1) Tau: Genetics, Biochemistry and Treatment Target
525	Urso Student Fellowship	Titus John	Duke University Durham, NC	2014	\$ 3,000	(6) Clinical and Laboratory Treatment-Oriented Research
526	Understanding the Relative Contributions of Genetic Risk Factors in PSP	Aimee Kao, MD, PhD	University of California, San Diego San Diego, CA	2014	\$ 100,000	(3) Non-Tau Based Genetic Studies
527	Elucidating PSP Genotype-Phenotype Relationships Using Human Isogenic iPSCs	John W. Steele, PhD Lawrence S. B. Goldstein, PhD	University of California, San Diego San Diego, CA	2014	\$ 100,000	(3) Non-Tau Based Genetic Studies
528	Selective Cell Vulnerability in MSA	Eduardo Benarroch, MD	Mayo Clinic Rochester, MN	2014	\$ 25,000	(2) Non-Tau Based Pathologies: Mitochondrial, Radicals, Cell Death
529	Spreading of a Synuclein Pathology in MSA	Johannes Brettschneider, MD	University of Ulm Ulm, Germany	2014	\$ 25,000	(2) Non-Tau Based Pathologies: Mitochondrial, Radicals, Cell Death
<b>159 RESEARCH GRANTS FUNDED THROUGH JUNE 30, 2014</b>					<b>\$12,767,340</b>	